Cancer pain market will likely to generate revenue of $7,545 million by 2025 |Top 3 Key players are Aoxing Pharmaceutical Company, BioDelivery Sciences International, Daiichi Sankyo Co.

According to a new report published by Allied Market Research, titled,"Cancer Pain Market by Type and Application: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,"the global cancer pain market was valued at $5,285 million in 2017, and is expected to reach $7,545 million by 2025, growing at a CAGR of 4.5% from 2018 to 2025.

Download the Sample Report @ http://bit.ly/2OZdLhH

Cancer pain is chronic in nature and is commonly associated with cancer. It results from tissue damage, either due to the disease itself or due to different treatments such as chemotherapy, radiotherapy, or surgery. Cancer pain drugs are expected to exhibit significant market growth during the forecast period due to growth in demand for the drugs, surge in prevalence of cancer across the globe, increase in number of R&D activities to develop ideal cancer pain medications, and rise in the unmet needs for management of cancer pain.

Based on drug type, the global cancer pain market is categorized into opioids, non-opioids, and nerve blockers. The opioids segment was the major revenue contributor in 2017, and is anticipated to remain dominant during the forecast period due to increase in the adoption of opioids owing to rise in number of moderate to severe stage cancer patient population.

According to disease indication, the market is classified into lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer, and others. The lung cancer segment presently dominates the market and is expected to remain dominant during the forecast period due to increase in adoption of cancer pain medication for the treatment and rise in prevalence of lung cancer, globally.

For More Inquiry @ http://bit.ly/2KdeiwT

Key Findings of the Cancer Pain Market:
• Based on drug type, the opioids segment is expected to experience rapid growth in the market and is projected to grow at a CAGR of 5.0% from 2018 to 2025.
• Based on disease indication, the lung cancer segment held more than one-fifth of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
• Based on region, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 5.4% during the forecast period.

North America accounted for more than one-third of the global market share in 2017 and is expected to remain dominant throughout the forecast period. This was attributed to the increase in demand for cancer pain therapeutics, high prevalence of cancer, wide availability of cancer pain drugs and trained medical professionals, and supportive reimbursement policies in the healthcare system.

Asia-Pacific is expected to experience the highest growth rate during the forecast period majorly due to surge in incidence of cancer, with increase in adoption of cancer pain drugs for treatment of cancer.

Contact Us:-
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

About Us:-
Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.